Follow us...

 

Search News Archives

Monthly Newsletter

Lab Bulletin January Newsletter

 

VIEW THE LATEST ISSUE

SUBSCRIBE Here

News Channels

 

New Laboratory Products

Lab News

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature

Videos

Events | Webinars

 

 

Conferences | Events

MyCartis Launches Evalution, a Next Generation Multiplex Biomarker Analysis Platform

publication date: Oct 29, 2014
 | 
author/source: MyCartis

MyCartis today announced the launch of Evalution™, a multiplex biomarker analysis platform for the life sciences research market. 

MyCartisEvalution™ is MyCartis’ digital multiplex analysis platform tailored to clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic acid-based biomarkers, delivering high quality data and rapid results. Evalution™ provides an integrated reaction and detection environment and simultaneous analysis of large numbers of analytes per assay.

Biocartis’ Swiss business unit Evalution™ and Belgian-based Pronota NV have recently joined forces in MyCartis NV. The combination of the Evalution™ platform as designed by Biocartis, and Pronota’s portfolio of validated biomarkers will deliver state-of-the-art solutions for a range of diseases in the fields of cardiovascular and women's health. 

"We believe that every individual has the right to good health. But we know that the current health model of ‘one size fits all’ is unsustainable", said Paul Ladestein, CEO of MyCartis. “By developing biomarker analysis solutions at the forefront of innovation we want to improve healthcare worldwide. Our next generation multiplexing platform Evalution™ will support researchers to better understand the role of biomarkers in early disease and risk diagnosis and patient management. Evalution™ can analyse an individual’s protein and molecular profile in a single assay plate”. 

Besides serving the research community, MyCartis also engages in licensing opportunities with companies aiming to develop their own commercial applications on the Evalution™ platform. Furthermore, MyCartis also develops and validates novel applications with simpler assay formats and unique biomarkers for a range of diseases. 

The launch of Evalution™ was announced at the HUPO event in Madrid. MyCartis also launches a new brand identity, including a new website and a blog, in which key opinion leaders and experts in biomarker research and personalized healthcare are interviewed.


more about mycartis




 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


 

Media Partners